The top 20 pharmaceutical companies have implemented a raft of new initiatives in the last two years. Yet in two important areas, progress remains static.

› Go to Key Findings

The industry pipeline is concentrated on five diseases. Five companies are developing more than half the products for developing countries.

› Go to Key Findings

Half of the companies in the Index are developing medicines tailored for children, with 7% of the overall research pipeline being devoted to “child-size” medicine.

› Go to Key Findings

More companies are tailoring their prices to different segments of national populations.

› Go to Key Findings

Home

Analysis Highlights

Download the report

Download the report

2014 Index Ranking

Latest News

Access to Medicine Index receives funds from the Postcode Loterij

27 January 2015 |

The Postcode Loterij in the Netherlands has awarded one of its 2015 annual grants to the Access to Medicine Foundation. The cheque was presented at the Postcode Loterij’s annual ‘Goed Geld Gala’ event in Amsterdam on 26 January.

› Read more

2014 Access to Medicine Index at the European Parliament – open invitation

22 January 2015 |
On 4 February, the 2014 Access to Medicine Index will be launched at the European Parliament in Brussels. Index Head of Research, Jayasree K. Iyer, will present the latest ranking of the top 20 global pharmaceutical companies.› Read more

Davos 2015: Wim Leereveld on health systems design

19 January 2015 |
On January 22, during the World Economic Forum Annual Meeting, Index CEO and founder Wim Leereveld will be in Davos to discuss the strategic design of health systems, including how to select, incubate and scale up those initiatives that hold the most promise. › Read more

Inside the 2014 Access to Medicine Index investor meetings

20 December 2014 |
In the weeks following the publication of the 2014 Access to Medicine Index, four investor meetings about the new Index took place: in London, Paris, Basel and New York City. Here we provide an overview of the central themes of discussion at these events.› Read more

Licensing medicines for HIV/AIDS: critical mechanism for ending the epidemic

1 December 2014 |
For World Aids Day, the Access to Medicine Index has analysed the licensing practices of the top 20 research-based pharmaceutical companies to assess how they are contributing to global efforts to combat HIV/AIDS.› Read more

What Leaders Say

Dr. Margaret Chan
Director-General, World Health Organization
"The Access to Medicine Index is a very important project. What gets measured, gets done."
Bill Gates
Chairman of Microsoft Corporation, Co-Chair and Trustee of the Bill & Melinda Gates Foundation
"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."
Justine Greening
Justine Greening
Secretary of State for International Development, The Rt Hon Justine Greening MP
This year’s index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries.
Lilianne Ploumen
Minister for Foreign Trade and Development Cooperation, the Netherlands
“The Access to Medicine Index mobilizes the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment.”
Knut Kjaer
Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM) (1997-2007)
"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

In the Media

2014 Index findings in the Pharmaceutical Journal

19 January 2015 |

The Pharmaceutical Journal in London creates an infographic of a range of findings from the 2014 Access to Medicine Index, including insights into the development of innovative and adapted products, equitable pricing strategies and local capacity building initiatives.

› Read more

Tara Prasad comments on vaccine pricing in De Volkskrant

27 January 2015 |

Writing in Dutch national newspaper De Volkskrant, Lisa Koetsenruijter covers the rises in vaccine prices over recent years.

› Read more

Wim Leereveld on BNR News Radio (Dutch)

19 January 2015 |

In a detailed 30-minute interview, Wim Leereveld talks to Paul van Liempt about how the Access to Medicine Index has evolved since its beginnings in 2003, and about the role it now plays in stimulating global pharmaceutical companies to help change the world.

› Read more

The New York Times covers the leaders, risers and fallers in the 2014 Index

2 December 2014 |

Donald McNeil reports GSK's No.1 postition, also noting that more than half of the companies in the 2014 Index are developing paediatric formulations of important drugs.

› Read more

Wall Street Journal uses 2014 Index findings to balance debate

18 November 2014 |

Ed Silverman covers the findings of the 2014 Index, providing nuance in the debate about the role of pharmaceutical companies. He reports that many drug makers are, by and large, making headway for access to medicine.

› Read more